The specific objectives of this project are: (a) to synthesize congeners of synthetic compounds with confirmed activity; (b) to design and synthesize prodrugs and other compounds that possess elements of both congener and prodrugs; (c) to synthesize compounds related to products of natural origin and other related heterocycles. There are several compounds in the NCI files, where progress is hampered by sub-DN2 level activity, poor solubility and/or stability. In an attempt to overcome these problems, and, in addition, make possible the flow of new compounds specifically designed to mitigate these difficulties, we propose to continue this project. The objectives are to design and synthesize (1) congeners of lead compounds to enhance the activity or broaden the antitumor spectrum; (2) prodrugs that are chemically altered transport forms of compounds to modify both biological and pharmaceutical properties, such as (a) improved bio-availability in increasing aqueous solubility; (b) increased compound stability; and (3) compounds related to products of natural origin. These modifications may include partial structures, analogs and novel heterocycles.
| Cushman, M; Kanamathareddy, S; De Clercq, E et al. (1991) Synthesis and anti-HIV activities of low molecular weight aurintricarboxylic acid fragments and related compounds. J Med Chem 34:337-42 |
| Cushman, M; Nagarathnam, D; Gopal, D et al. (1991) Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization. J Med Chem 34:2579-88 |
| Cushman, M; Chinnasamy, P; Chakraborti, A K et al. (1990) Synthesis of [beta-(4-pyridyl-1-oxide)-L-alanine4]-angiotensin I as a potential suicide substrate for protein-tyrosine kinases. Int J Pept Protein Res 36:538-43 |
